289 related articles for article (PubMed ID: 32516282)
1. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2).
Baker J; Block SL; Matharu B; Burleigh Macutkiewicz L; Wildum S; Dimonaco S; Collinson N; Clinch B; Piedra PA
Pediatr Infect Dis J; 2020 Aug; 39(8):700-705. PubMed ID: 32516282
[TBL] [Abstract][Full Text] [Related]
2. Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study.
Yokoyama T; Sakaguchi H; Ishibashi T; Shishido T; Piedra PA; Sato C; Tsuchiya K; Uehara T
Pediatr Infect Dis J; 2020 Aug; 39(8):706-712. PubMed ID: 32433222
[TBL] [Abstract][Full Text] [Related]
3. Clinical and virological outcomes with baloxavir compared with oseltamivir in pediatric patients aged 6 to < 12 years with influenza: an open-label, randomized, active-controlled trial protocol.
Ishiguro N; Morioka I; Nakano T; Furukawa M; Tanaka S; Kinoshita M; Manabe A
BMC Infect Dis; 2021 Aug; 21(1):777. PubMed ID: 34372769
[TBL] [Abstract][Full Text] [Related]
4. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
Hayden FG; Sugaya N; Hirotsu N; Lee N; de Jong MD; Hurt AC; Ishida T; Sekino H; Yamada K; Portsmouth S; Kawaguchi K; Shishido T; Arai M; Tsuchiya K; Uehara T; Watanabe A;
N Engl J Med; 2018 Sep; 379(10):913-923. PubMed ID: 30184455
[TBL] [Abstract][Full Text] [Related]
5. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice: A postmarketing surveillance of more than 3000 patients.
Nakazawa M; Hara K; Komeda T; Ogura E
J Infect Chemother; 2020 Jul; 26(7):729-735. PubMed ID: 32409018
[TBL] [Abstract][Full Text] [Related]
7. The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets.
Kitano M; Matsuzaki T; Oka R; Baba K; Noda T; Yoshida Y; Sato K; Kiyota K; Mizutare T; Yoshida R; Sato A; Kamimori H; Shishido T; Naito A
Influenza Other Respir Viruses; 2020 Nov; 14(6):710-719. PubMed ID: 32533654
[TBL] [Abstract][Full Text] [Related]
8. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
Saito R; Osada H; Wagatsuma K; Chon I; Sato I; Kawashima T; Saito T; Kodo N; Ono Y; Shimada Y; Phyu W; Shobugawa Y
Antiviral Res; 2020 Nov; 183():104951. PubMed ID: 32987032
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials.
Kuo YC; Lai CC; Wang YH; Chen CH; Wang CY
J Microbiol Immunol Infect; 2021 Oct; 54(5):865-875. PubMed ID: 34020891
[TBL] [Abstract][Full Text] [Related]
10. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.
Ikematsu H; Hayden FG; Kawaguchi K; Kinoshita M; de Jong MD; Lee N; Takashima S; Noshi T; Tsuchiya K; Uehara T
N Engl J Med; 2020 Jul; 383(4):309-320. PubMed ID: 32640124
[TBL] [Abstract][Full Text] [Related]
11. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG
Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195
[TBL] [Abstract][Full Text] [Related]
12. Baloxavir Treatment in Adolescents With Acute Influenza: Subgroup Analysis From the CAPSTONE-1 Trial.
Portsmouth S; Hayden FG; Kawaguchi K; Ishibashi T; Kinoshita M; Shishido T; Tsuchiya K; Uehara T
J Pediatric Infect Dis Soc; 2021 Apr; 10(4):477-484. PubMed ID: 33340316
[TBL] [Abstract][Full Text] [Related]
13. Baloxavir Marboxil Treatment of Nude Mice Infected With Influenza A Virus.
Kiso M; Yamayoshi S; Murakami J; Kawaoka Y
J Infect Dis; 2020 Apr; 221(10):1699-1702. PubMed ID: 31837268
[TBL] [Abstract][Full Text] [Related]
14. Early combination treatment with baloxavir and peramivir for hospitalized adults with influenza A in Yokohama, Japan.
Yoshimura Y; Sasaki H; Horiuchi H; Miyata N; Kawakami C; Usuku S; Tachikawa N
Eur J Clin Microbiol Infect Dis; 2020 Sep; 39(9):1637-1640. PubMed ID: 32291543
[TBL] [Abstract][Full Text] [Related]
15. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.
Kumar D; Ison MG; Mira JP; Welte T; Hwan Ha J; Hui DS; Zhong N; Saito T; Katugampola L; Collinson N; Williams S; Wildum S; Ackrill A; Clinch B; Lee N
Lancet Infect Dis; 2022 May; 22(5):718-730. PubMed ID: 35085510
[TBL] [Abstract][Full Text] [Related]
16. A Pharmacokinetics-Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B.
Retout S; De Buck S; Jolivet S; Duval V; Cosson V
Clin Pharmacol Ther; 2022 Aug; 112(2):372-381. PubMed ID: 35585696
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection.
Ando Y; Noshi T; Sato K; Ishibashi T; Yoshida Y; Hasegawa T; Onishi M; Kitano M; Oka R; Kawai M; Yoshida R; Sato A; Shishido T; Naito A
J Antimicrob Chemother; 2021 Jan; 76(1):189-198. PubMed ID: 33035324
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis.
Liu JW; Lin SH; Wang LC; Chiu HY; Lee JA
JAMA Netw Open; 2021 Aug; 4(8):e2119151. PubMed ID: 34387680
[TBL] [Abstract][Full Text] [Related]
19. Rapid health technology assessment of the novel endonuclease inhibitor baloxavir for the treatment of influenza.
Huang G; Tian Y; Cui W; Zhang X; Zhao Y; Liu X
J Chemother; 2024 Jul; 36(4):267-282. PubMed ID: 37767970
[TBL] [Abstract][Full Text] [Related]
20. Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir.
Salvatore M; Laplante JM; Soave R; Orfali N; Plate M; van Besien K; St George K
Transpl Infect Dis; 2020 Aug; 22(4):e13336. PubMed ID: 32449254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
